Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.

Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.

A new tool puts this year's measles toll at nearly $83 million as global health experts weigh whether the US has lost elimination status.

Eosinophil thresholds and documentation rules shape COPD biologic access. At ERS 2026, experts discussed biomarkers, delays, and multidisciplinary care.

The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.

In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.

The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.

GOLD leaders say COPD is diagnosed too late and its smoking-only image is outdated, and the 2027 report puts rehab and non–drug care up front.